Leidos Shares Fall Despite Earnings Beat as Guidance Disappoints

BenzingaBenzinga
|||1 min read
Key Takeaway

Leidos beat earnings but shares fell 6% due to disappointing revenue and weak 2026 guidance, reflecting government budget uncertainties and operational challenges.

Leidos Shares Fall Despite Earnings Beat as Guidance Disappoints

Leidos Holdings reported fourth-quarter financial results that failed to satisfy investors despite exceeding earnings expectations, with shares declining 6.16% following the announcement. The defense contractor posted adjusted earnings per share of $2.76, surpassing analyst estimates, but revenue of $4.21 billion fell short of expectations and declined 4% year-over-year, primarily due to disruptions from the federal government shutdown during the period.

The company's forward guidance proved to be the primary driver of investor concern, with Leidos issuing fiscal 2026 projections below consensus estimates. This cautious outlook has raised questions about the trajectory of the company's core business segments amid ongoing government budget uncertainties and operational challenges that extended into the new fiscal year.

Leidos announced a strategic acquisition of Entrust, a power design firm, for $2.4 billion as part of efforts to expand its portfolio and capabilities. The deal represents management's confidence in long-term growth opportunities, though investors have focused more heavily on the company's tempered near-term guidance and revenue headwinds.

Source: Benzinga

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

MVST Stock Plunges 34% After Disastrous Earnings; Law Firm Launches Fraud Investigation

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

MVSTMVSTW
Benzinga

Mountain Commerce Bancorp Clears Regulatory Hurdles for Home BancShares Merger

Mountain Commerce Bancorp receives Federal Reserve and Arkansas regulatory approvals for merger with Home BancShares, expected to close in early Q2 2026.

HOMBMCBI
Benzinga

KB Home Shares Slide on 23% Revenue Decline, Margin Compression in Q1

KB Home stock fell 4.8% after Q1 earnings missed expectations, with revenue down 23% year-over-year and operating margins compressed to 3.1%.

KBH
The Motley Fool

Fluence Director Sells $165K in Stock Amid 200% Surge—What It Signals

Fluence Energy director sold $165K in shares via routine tax-driven RSU vesting, retaining majority stake. Stock's 200% surge raises valuation sustainability questions amid energy storage market maturation.

FLNC
Benzinga

Smithfield Foods Surges on Robust Q4 Earnings, Nathan's Famous Deal

Smithfield Foods beat Q4 expectations with 83-cent EPS, announced $450M Nathan's Famous acquisition at $102/share, projecting $1.3-$1.5B FY26 operating profit. Stock surged 4.13%.

SFDNATH
Benzinga

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.

GILDACLXGLPG